Back to Search
Start Over
Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer.
- Source :
- European Journal of Nuclear Medicine & Molecular Imaging; May2024, Vol. 51 Issue 6, p1763-1772, 10p
- Publication Year :
- 2024
-
Abstract
- Purpose: [<superscript>18</superscript>F]fluorodeoxyglucose ([<superscript>18</superscript>F]FDG) positron emission tomography/computed tomography (PET/CT) has limitations in prostate cancer (PCa) detection owing to low glycolysis in the primary tumour. Recently, prostate-specific membrane antigen (PSMA) PET/CT has been useful for biochemical failure detection and radioligand therapy (RLT) guidance. However, few studies have evaluated its use in primary prostate tumours using PSMA and [<superscript>18</superscript>F]FDG PET/CT. This study aimed to evaluate [<superscript>18</superscript>F]PSMA-1007 and [<superscript>18</superscript>F]FDG PET/CT for primary tumour detection and understand the association of metabolic heterogeneity with clinicopathological characteristics at staging and postoperatively. Method: This prospective study included 42 index tumours (27 acinar and 15 ductal-dominant) in 42 patients who underwent [<superscript>18</superscript>F]PSMA-1007 and [<superscript>18</superscript>F]FDG PET/CT and subsequent radical prostatectomy. All patients were followed for a median of 26 mo, and serum prostate-specific antigen levels were measured every 3 mo to evaluate biochemical failure. One-way analysis of variance, Tukey's multiple comparison test, and Fisher's exact test were performed. Results: All 42 index tumours were detected on [<superscript>18</superscript>F]PSMA-1007 PET/CT, whereas only 15 were detected on [<superscript>18</superscript>F]FDG PET/CT (62.3% vs. 37.7%, p < 0.0001). A high SUV<subscript>max</subscript> for [<superscript>18</superscript>F]PSMA-1007 was observed in tumours with high Gleason scores (GS 6–7 vs. GS 8–10; 12.1 vs. 20.1, p < 0.05). Tumours with [<superscript>18</superscript>F]FDG uptake were mostly ductal dominant (acinar-dominant 4/27; ductal-dominant; 11/15, p < 0.001), with lower [<superscript>18</superscript>F]PSMA-1007 uptake than tumours without [<superscript>18</superscript>F]FDG uptake (SUVmax 16.58 vs. 11.19, p < 0.001). There were 16.6% (7/42) of patients with pStage IV in whom the primary tumours were [<superscript>18</superscript>F]FDG positive. Biochemical failure was observed in 14.8% (4/27) of patients with [<superscript>18</superscript>F]FDG negative tumours but in 53.3% (8/15) of patients with [<superscript>18</superscript>F]FDG positive tumours (p = 0.013). Conclusions: [<superscript>18</superscript>F]PSMA-1007 PET/CT was superior to [<superscript>18</superscript>F]FDG PET/CT in detecting primary PCa. In contrast, tumours with [<superscript>18</superscript>F]FDG uptake are associated with larger size, a ductal-dominant type, and likely to undergo metastasis at staging and biochemical failure postoperatively. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 16197070
- Volume :
- 51
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- European Journal of Nuclear Medicine & Molecular Imaging
- Publication Type :
- Academic Journal
- Accession number :
- 176804768
- Full Text :
- https://doi.org/10.1007/s00259-023-06585-7